Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study

Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.
No abstract available

Publication types

  • Multicenter Study
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Cyclophosphamide / therapeutic use
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
  • Rituximab / therapeutic use
  • Vidarabine / therapeutic use

Substances

  • Rituximab
  • ibrutinib
  • fludarabine
  • Cyclophosphamide
  • Vidarabine